CPT1A Antibody - #DF12004

(21)   (13)  
製品: CPT1A Antibody
カタログ: DF12004
タンパク質の説明: Rabbit polyclonal antibody to CPT1A
アプリケーション: WB IHC
反応性: Human, Mouse, Rat
予測: Bovine, Dog
分子量: 86 kDa, 70 kDa; 88kD(Calculated).
ユニプロット: P50416
RRID: AB_2844809

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MS Report
HPLC Report
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
予測:
Bovine(85%), Dog(92%)
クローナリティ:
Polyclonal
特異性:
CPT1A Antibody detects endogenous levels of total CPT1A.
RRID:
AB_2844809
引用形式: Affinity Biosciences Cat# DF12004, RRID:AB_2844809.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

Carnitine O palmitoyltransferase 1 liver isoform; Carnitine O palmitoyltransferase I; Carnitine O palmitoyltransferase I liver isoform; Carnitine O-palmitoyltransferase 1; Carnitine O-palmitoyltransferase I; Carnitine palmitoyltransferase 1A (liver); Carnitine palmitoyltransferase 1A; Carnitine palmitoyltransferase I; Carnitine palmitoyltransferase I liver; CPT 1; CPT I; CPT1; CPT1 L; CPT1-L; Cpt1a; CPT1A_HUMAN; CPTI; CPTI-L; L CPT1; liver isoform;

免疫原

免疫原:
Uniprot:

P50416(CPT1A_HUMAN) >>Visit HPA database.

遺伝子(ID):
CPT1A(1374)
発現特異性:
P50416 CPT1A_HUMAN:

Strong expression in kidney and heart, and lower in liver and skeletal muscle.

タンパク質配列:
MAEAHQAVAFQFTVTPDGIDLRLSHEALRQIYLSGLHSWKKKFIRFKNGIITGVYPASPSSWLIVVVGVMTTMYAKIDPSLGIIAKINRTLETANCMSSQTKNVVSGVLFGTGLWVALIVTMRYSLKVLLSYHGWMFTEHGKMSRATKIWMGMVKIFSGRKPMLYSFQTSLPRLPVPAVKDTVNRYLQSVRPLMKEEDFKRMTALAQDFAVGLGPRLQWYLKLKSWWATNYVSDWWEEYIYLRGRGPLMVNSNYYAMDLLYILPTHIQAARAGNAIHAILLYRRKLDREEIKPIRLLGSTIPLCSAQWERMFNTSRIPGEETDTIQHMRDSKHIVVYHRGRYFKVWLYHDGRLLKPREMEQQMQRILDNTSEPQPGEARLAALTAGDRVPWARCRQAYFGRGKNKQSLDAVEKAAFFVTLDETEEGYRSEDPDTSMDSYAKSLLHGRCYDRWFDKSFTFVVFKNGKMGLNAEHSWADAPIVAHLWEYVMSIDSLQLGYAEDGHCKGDINPNIPYPTRLQWDIPGECQEVIETSLNTANLLANDVDFHSFPFVAFGKGIIKKCRTSPDAFVQLALQLAHYKDMGKFCLTYEASMTRLFREGRTETVRSCTTESCDFVRAMVDPAQTVEQRLKLFKLASEKHQHMYRLAMTGSGIDRHLFCLYVVSKYLAVESPFLKEVLSEPWRLSTSQTPQQQVELFDLENNPEYVSSGGGFGPVADDGYGVSYILVGENLINFHISSKFSCPETDSHRFGRHLKEAMTDIITLFGLSSNSKK

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Dog
92
Bovine
85
Pig
77
Sheep
77
Horse
69
Xenopus
69
Zebrafish
0
Chicken
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P50416 基板として

Site PTM Type Enzyme
K86 Ubiquitination
S106 Phosphorylation
S158 Phosphorylation
K161 Ubiquitination
Y165 Phosphorylation
K180 Ubiquitination
K195 Ubiquitination
K200 Ubiquitination
K292 Ubiquitination
T322 Phosphorylation
S371 Phosphorylation
K405 Ubiquitination
K441 Ubiquitination
Y514 Phosphorylation
K634 Ubiquitination
S671 Phosphorylation
K675 Ubiquitination
K755 Ubiquitination
S771 Phosphorylation
K772 Ubiquitination

研究背景

機能:

Catalyzes the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the mitochondrion. Plays an important role in triglyceride metabolism.

細胞の位置付け:

Mitochondrion outer membrane>Multi-pass membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Strong expression in kidney and heart, and lower in liver and skeletal muscle.

サブユニット構造:

Homohexamer and homotrimer. Identified in a complex that contains at least CPT1A, ACSL1 and VDAC1. Also identified in complexes with ACSL1 and VDAC2 and VDAC3 (By similarity).

タンパク質ファミリー:

A conformation change in the N-terminal region spanning the first 42 residues plays an important role in the regulation of enzyme activity by malonyl-CoA.

Belongs to the carnitine/choline acetyltransferase family.

研究領域

· Environmental Information Processing > Signal transduction > AMPK signaling pathway.   (View pathway)

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Metabolism > Lipid metabolism > Fatty acid degradation.

· Metabolism > Global and overview maps > Fatty acid metabolism.

· Organismal Systems > Endocrine system > PPAR signaling pathway.

· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.

· Organismal Systems > Endocrine system > Glucagon signaling pathway.

参考文献

1). Dioscin ameliorates murine ulcerative colitis by regulating macrophage polarization. Pharmacological research, 2021 (PubMed: 34343656) [IF=9.1]
2). Dihydroartemisinin is potential therapeutics for treating late-stage CRC by targeting the elevated c-Myc level. Cell Death & Disease, 2021 (PubMed: 34741022) [IF=8.1]

Application: WB    Species: Mouse    Sample: xenograft tissues

Fig. 4 Dihydroartemisinin reduces c-Myc transcriptional activity, and its downstream targets involved in lipid metabolism. A c-Myc reporter activity in DLD-1 and HCT116 cells after dihydroartemisinin (DHA, 10 µM) treatment. The data are shown as means ± SEM, n = 3 independent experiments, *p 
3). Polyoxometalates Ameliorate Metabolic Dysfunction-Associated Steatotic Liver Disease by Activating the AMPK Signaling Pathway. International journal of nanomedicine, 2024 (PubMed: 39479173) [IF=8.0]
4). Natural Linoleic Acid from Marine Fungus Eutypella sp. F0219 Blocks KEAP1/NRF2 Interaction and Ameliorates MASLD by Targeting FABP4. Free radical biology & medicine, 2024 (PubMed: 39299527) [IF=7.1]
5). Yogurt-derived Lactobacillus plantarum Q16 alleviated high-fat diet-induced non-alcoholic fatty liver disease in mice. Food Science and Human Wellness, 2022 [IF=7.0]

Application: WB    Species: Mouse    Sample:

Fig. 5. Effects ofL. plantarum Q16 on key proteins involved in hepatic lipid metabolism in HFD-fed obese mice. Data are presented as mean ± SD (n = 6). Different lowercase alphabet letters were significantly different at the level of P < 0.05.
6). β-patchoulene improves lipid metabolism to alleviate non-alcoholic fatty liver disease via activating AMPK signaling pathway. BIOMEDICINE & PHARMACOTHERAPY, 2021 (PubMed: 33341045) [IF=6.9]

Application: WB    Species: Human    Sample: L02 cell

Fig. 6. β-PAE promotes the expression of hepatic lipid oxidation-related proteins and genes in HFD-fed rats. (A–G) Western blot analysis on the expression of SIRT1, PGC-1α, PPARα, FGF21, CPT-1a and ACOX1; (H–K) The mRNA expression of SIRT1, PPARα, CPT-1a and ACOX1. Data are presented as the mean ± SD (n = 6~8). ##p < 0.01 vs. NC group; *p < 0.05, **p < 0.01 vs. Model group.
7). Shenqi Pill alleviates acetaminophen-induced liver injury: a comprehensive strategy of network pharmacology and spectrum-effect relationship reveals mechanisms and active components. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2024 (PubMed: 39303509) [IF=6.7]
8). Shikonin ameliorated LPS-induced acute lung injury in mice via modulating MCU-mediated mitochondrial Ca2+ and macrophage polarization. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2024 (PubMed: 39366155) [IF=6.7]
9). Probiotic Yogurt Alleviates High-Fat Diet-Induced Lipid Accumulation and Insulin Resistance in Mice via the Adiponectin Pathway. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2023 (PubMed: 36695046) [IF=5.7]
10). Roxadustat, a Hypoxia-Inducible Factor 1α Activator, Attenuates Both Long-and Short-Term Alcohol-Induced Alcoholic Liver Disease. Frontiers in Pharmacology, 2022 (PubMed: 35620283) [IF=5.6]

Application: WB    Species: Human    Sample: HepG2 cells

FIGURE 2 Roxadustat attenuates lipid accumulation by increasing PPARα protein expression in the liver and reducing FASN levels in HepG2 cells. (A–D) Liver samples were collected from mice in Figure 1 and used for the following experiments. Liver frozen sections were stained with Oil Red O staining (A); triglyceride content was determined using an assay kit (B); mRNA expression of DGAT1 and FASN was determined by qRT-PCR (C); protein expression of PPARα and CPT1A was determined by Western blot with quantitative analysis of band density (D); (E) HepG2 cells were treated with roxadustat at indicated concentrations for 24 h. Protein expression of FASN and HIF-1α was determined by Western blot with quantitative analysis of band density (right panels); (F,G) HepG2 cells were transfected with scrambled siRNA (si-NC) or HIF-1α siRNA (si-HIF-1α) for 24 h, and then treated with roxadustat for 24 h. Protein expression of FASN, PPARα, and HIF-1α was determined by Western blot with quantitative analysis of band density (F); lipid accumulation was determined by Oil Red O staining with quantitative analysis (G). *, p < 0.05; **, p < 0.01; ***, p < 0.001 vs ctrl; # p < 0.05, ###, p < 0.001 vs ALD group (n ≥ 5); Roxa: roxadustat.
もっと読みます

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.